The FDA recently changed how it approves osteoporosis medications, allowing bone density measurements instead of actual fracture prevention data, but experts worry this speed-focused approach may compromise patient safety by missing long-term risks. Fewer than 15% of patients who suffer fractures from osteoporosis receive treatment, and only 10 to 21% of hip and vertebral fracture patients get a bone density scan within 12 months, leaving a significant gap in prevention and care.

What Changed in How Osteoporosis Drugs Get Approved?

The FDA now permits bone mineral density (BMD) as a surrogate approval endpoint instead of requiring clinical fracture data. This substantially reduces both trial size and duration, presumably to promote innovation and accelerate drug development. The shift was driven by industry and bone researchers using pooled patient data showing a strong correlation between BMD and fracture risk. However, this approach has a troubling precedent: a fluoride trial raised spine BMD more than any agent tested yet increased fracture risk, potentially undercutting BMD as a universally reliable surrogate.

The concern runs deeper than one failed drug. Trabecular bone (the spongy interior) remodels over approximately five years, while cortical bone (the dense outer layer) takes roughly twice that long. Short clinical trials lasting less than two years may miss true outcomes because medications that inhibit bone turnover may not show major effects during that brief window. Yet during this period, gradual microdamage accumulates, weakens bone, and raises the risk for atypical femoral fractures, a serious complication seen with bisphosphonates and denosumab.

Which Osteoporosis Drugs Have Shown Hidden Safety Problems?

Several medications have revealed safety signals only after longer observation periods. Strontium ranelate lost European Union approval for cardiovascular harm despite raising BMD measurements. Cathepsin K inhibitors showed increased stroke risk after two years of use. Anabolic-then-antiresorptive agents, including teriparatide, denosumab, and romosozumab, also lose their BMD gains once patients stop taking them, meaning short trials may not capture the full picture of what happens when treatment ends.

• Atypical Femoral Fractures: Long-term use of bone-suppressing drugs like bisphosphonates and denosumab can cause unusual breaks in the thighbone that reflect cumulative microdamage from turnover suppression, suggesting duration-limiting strategies remain warranted.
• Cardiovascular Complications: Some osteoporosis medications have shown increased stroke or clotting risks that only emerged after extended follow-up, highlighting the danger of short-term trials.
• Loss of Bone Gains: Newer anabolic agents lose their bone-building benefits once discontinued, meaning patients may need indefinite treatment or face rapid bone loss.

When Should Osteoporosis Prevention Actually Begin?

Rather than waiting for new drugs, experts argue that the real opportunity lies in earlier intervention. Bone loss is steepest in the year before and after a woman's final menstrual period, making perimenopausal screening and prevention more promising than new drug approvals alone. A four-year randomized controlled trial in women aged 40 to 60 showed that placebo recipients lost 2.9% of hip bone mineral density, while those taking alendronate gained 1.4%, and those on estrogen gained 3.7%.

The evidence for early intervention is compelling. The Study of Osteoporotic Fractures demonstrated durable fracture-risk reduction with estrogen use averaging 35 years, without atypical fracture or osteonecrosis of the jaw (ONJ) risk. Concerns about cardiovascular harm from hormone therapy were age-dependent; benefits appeared near menopause while harm occurred in older women. Transdermal estrogen now appears to lower clotting risk further compared to oral formulations.

A single zoledronate dose in women aged 50 to 60 also cut fracture incidence to 6.6% compared with 11.1% in the placebo group, with resorption markers rebounding over time. This approach potentially avoids long-duration ONJ and atypical fracture risk, though confirmatory trials are needed.

How to Advocate for Better Osteoporosis Care

• Ask About Screening Timing: If you are approaching menopause, discuss bone density screening with your doctor now rather than waiting until age 65, since the perimenopausal years represent the highest-yield prevention window.
• Request Post-Fracture Evaluation: If you suffer a hip, vertebral, or other major fracture, ensure your doctor orders a bone density scan within 12 months and discusses treatment options, since fewer than 21% of fracture patients currently receive this standard care.
• Discuss Long-Term Safety: When considering osteoporosis medications, ask your doctor about the duration of treatment planned and what happens when you stop, especially for newer anabolic agents that lose their benefits after discontinuation.
• Explore Perimenopausal Options: Talk with your healthcare provider about whether perimenopausal hormone therapy or early bisphosphonate use might be appropriate for your individual risk profile, rather than waiting for newer drugs.

"There are many unmet needs and challenges in osteoporosis," noted Dr. Susan Ott in a recent JAMA Viewpoints article addressing regulatory changes and new drug development. "Fewer than 15% of post-fracture patients get treated, and only 10 to 21% of hip and vertebral fracture patients receive a DXA scan within 12 months."

Dr. Susan Ott, Author of JAMA Viewpoints Article on Osteoporosis Prevention

The push for faster drug approvals reflects genuine innovation in osteoporosis treatment, but it also reflects a troubling gap between regulatory speed and patient safety. The real breakthrough may not be a new medication, but rather a shift in when and how we screen for bone loss and intervene early, before fractures occur. Until approval pathways require longer-term safety data, patients and doctors should remain cautious about newer agents and consider the proven benefits of perimenopausal prevention strategies.